{"id":"W2134021845","doi":"10.1016/s1470-2045(11)70338-2","title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal; Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Aflibercept; Paracentesis; Ascites; Placebo; Surgery; Population; Clinical endpoint; Internal medicine; Ovarian cancer; Chemotherapy; Bevacizumab; Gastroenterology; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00115534,0.001645259,0.004619831,0.0005852967,0.0003472049,0.001052436,0.0008966925,0.002332828,0.004961811],"category_scores_gemma":[0.001684965,0.0008783022,0.001664134,0.0006223195,0.001338958,0.001145897,0.0003874156,0.002824044,0.0008669527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000486999,"about_ca_system_score_gemma":0.0008107623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007902745,"about_ca_topic_score_gemma":0.001332599,"domain_scores_codex":[0.9995394,0.0002054629,0.00003665992,0.00008317332,0.0000446043,0.00009071515],"domain_scores_gemma":[0.9992753,0.000229673,0.0001685565,0.00005610634,0.00004408821,0.0002263019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970099,0.004919913,0.0003147841,0.001120359,0.0006907542,0.00004575898,0.00004572395,0.0002128872,0.003152371,0.0000754543,0.0005802959,0.01874278],"study_design_scores_gemma":[0.963476,0.03498632,0.0006118148,0.00002027413,0.0001833185,0.00002106048,0.000009360542,0.0001572181,0.0001942988,0.00004096237,0.0002903375,0.000009004255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771389,0.0120373,0.001446008,0.0008239637,0.0012228,0.00402365,0.0009805203,0.0002261686,0.00210063],"genre_scores_gemma":[0.9825451,0.006265044,0.001899908,0.001184702,0.0009497281,0.003346694,0.0007491533,0.00003357776,0.003026044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004961811,"threshold_uncertainty_score":0.01659894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06439106428427824,"score_gpt":0.3562637120626185,"score_spread":0.2918726477783403,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}